Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

Small-molecule drug discovery has traditionally focused on occupancy of a binding site that
directly affects protein function, and this approach typically precludes targeting proteins that …

Epigenetic processes govern prostate cancer (PCa) biology, as evidenced by the
dependency of PCa cells on the androgen receptor (AR), a prostate master transcription …

Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma (PC) and
represents the major therapeutic target for treating metastatic prostate cancer (mPC) …

During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …

Vitamin D is not really a vitamin but the precursor to the potent steroid hormone calcitriol,
which has widespread actions throughout the body. Calcitriol regulates numerous cellular …

Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

Androgens and androgen receptors (AR) play a pivotal role in expression of the male
phenotype. Several diseases, such as androgen insensitivity syndrome (AIS) and prostate …

Genome sequencing and gene expression analyses of prostate tumours have highlighted
the potential importance of genetic and epigenetic changes observed in WNT signalling …

Background Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-
receptor–signaling pathway, the major driver of prostate-cancer growth. We aimed to …